|
Market Report
|
 Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products
The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market.
|
|
Read more...
|
|
|
Company Report
|
Business Blogging for Pharma
Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies' products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries.
|
|
Read more...
|
|
|
Market Report
|
 Hospital Antibacterials A market beyond MRSA
The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.
|
|
Read more...
|
|
|
Product Report
|
Regulatory and development issues hurdles exist but are surmountable
Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars presents many challenges and potential pitfalls.
|
|
Read more...
|
|
|
Market Report
|
Online Pharmacies - Implications for the Pharmaceutical Industry
Online pharmacies are playing an increasing role in the prescription pharmaceutical industry as patients seek the convenience and in some cases cost benefits that they can provide. However while online pharmacies offer considerable benefits there are also risks attached to their increasing role.
|
|
Read more...
|
|
|
Product Report
|
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. The report assesses how these players will be insulated from the impact of generic competition as a result of mAb market penetration.
|
|
Read more...
|
|
|
Market Report
|
Migraine - Opportunities will exist in the wake of generic attack
With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.
|
|
Read more...
|
|
|
Market Report
|
Epilepsy - Companies committed to the cause will reap the benefits
The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near to mid term will be brought about by the occurrence of key patent expiries and new drugs launches.
|
|
Read more...
|
|
|
Market Report
|
Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market
The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCB's Vimpat (lacosamide).
|
|
Read more...
|
|
|
Market Report
|
NICE: its impact on the UK healthcare system and beyond
NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated considerable attention globally.
|
|
Read more...
|
|
|
Market Report
|
Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.
|
|
Read more...
|
|
|
Market Report
|
Cancer Overview - Increasing diversity offers both high risk and reward
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
|
|
Read more...
|
|
|
Market Report
|
Strategic issues - Potential remains uncertain
Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.
|
|
Read more...
|
|
|
Market Report
|
HIV Therapy Dynamics
Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.
|
|
Read more...
|
|
|
Market Report
|
Upper GI Disorders - Innovation needed to overcome generic threat
The upper GI market, defined as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD) and dyspepsia indications, achieved sales of just over $19 billion in 2006, with minimal growth since 2005. All major PPI brands will lose patent protection in the next 10 years, resulting in a major increase in generics and a declining market value.
|
|
Read more...
|
|
|
Market Report
|
Allergic Rhinitis Market
The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.
|
|
Read more...
|
|
|
Market Report
|
Infertility - Optimizing a market bounded by social opinion and physician preference
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
|
|
Read more...
|
|
|
Market Report
|
Antithrombotics - Market expands as disease management focuses on prevention
Datamonitor expects the antithrombotics market to peak at just over $20 billion in 2012, across the seven major markets. The growth will be driven by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's Rendix - which are expected to launch simultaneously, in 2008.
|
|
Read more...
|
|
Farmavita.Net Journal 
